Background. Flow-metabolism coupling is thought to be deranged after traumatic brain injury, while the effects of propofol on¯ow-metabolism coupling are controversial. We have used a step increase in target plasma propofol concentration in head injured patients to explore¯ow-metabolism coupling in these patients.
1
Propofol is believed to maintain, or even improve, cerebral autoregulation; 2 3 indeed even high doses of this drug do not obtund autoregulation or carbon dioxide reactivity. 4 The effect of propofol on¯ow-metabolism coupling is more controversial, with at least one study demonstrating intact coupling. 5 However, a number of reports suggest that ow-metabolism coupling may be adversely in¯uenced by propofol, and both increases and decreases in cerebral oxygen extraction have been demonstrated with propofol.
3 6±8 Despite the fact that normal¯ow-metabolism coupling is believed to be retained in only a proportion of head injured patients 9 10 there is a paucity of data regarding the in¯uence of propofol on¯ow-metabolism coupling after traumatic brain injury. Equally, although high dose barbiturates are believed to be of bene®t in head-injured patients with refractory intracranial hypertension 11 there is a lack of data looking at how propofol induced EEG burstsuppression in¯uences cerebral oxygenation and metabolism.
Recent technical advances have allowed the development of implantable sensors that can measure regional tissue oxygenation (e.g. NeurotrendÔ sensor, Codman, USA) and regional tissue chemistry (microdialysis). The NeurotrendÔ sensor can also measure local carbon dioxide (Pb CO 2 ), pH, and temperature. Brain tissue oxygen probes and cerebral microdialysis increasingly are being used as monitoring tools in head-injured patients, both to aid the diagnosis of secondary injury and to guide therapeutic interventions.
Brain tissue oxygen monitors measure the local partial pressure of oxygen in the brain extracellular space (Pb O 2 ). Pb O 2 re¯ects the local balance between oxygen supply and demand, with Pb O 2 falling as either the supply (cerebral blood¯ow or arterial oxygen content) falls or the demand (cerebral metabolic rate of oxygen) increases. The arterialjugular venous oxygen difference (AVDO 2 ) re¯ects the global balance between oxygen supply and demand. Because Pb O 2 and AVDO 2 measurements both assess the relationship between oxygen supply and demand they can be used as surrogate markers of¯ow-metabolism coupling.
Microdialysis is a technique for collecting samples of extracellular¯uid; substrate and metabolite molecules (e.g. glucose, lactate, pyruvate, and glycerol) can then be analysed. Lactate and pyruvate concentrations are thought to re¯ect anaerobic and aerobic metabolism, respectively, with the lactate/pyruvate ratio being considered an important marker of the redox state of the tissue. Glycerol is thought to be a marker of cell membrane breakdown, whilst glucose levels represent a complicated balance between local blood¯ow, peripheral blood concentration, and cellular uptake. 13 We have combined microdialysis and tissue oxygen monitoring to investigate how a step increase in blood propofol concentration affects the relationship between cerebral oxygenation and metabolism after traumatic brain injury. Our hypothesis was that in non-ischaemic areas of the brain¯ow-metabolism coupling would remain intact; however, in ischaemic areas of the brain increased metabolic suppression would improve the ischaemic burden.
Methods
This study was approved by the local research ethics committee and written informed assent was obtained from the next of kin of all patients. Patients older than 16 yr with moderate to severe head injury requiring sedation, ventilation, and intracranial pressure monitoring were eligible for the study. Patients with coagulation disorders, unstable physiology, or who had received barbiturates or benzodiazepines for sedation were excluded.
Patients were managed according to Addenbrooke's Neurosciences Critical Care Unit protocols, 14 15 which include sedation with propofol and fentanyl, paralysis with atracurium, and support of cerebral perfusion pressure (CPP) to approximately 70 mm Hg. Monitored variables included ECG, peripheral oxygen saturation, end-tidal carbon dioxide, jugular venous oxygen saturation, and intracranial pressure. Apart from the propofol intervention, all other aspects of physiology were kept as stable as possible during the study.
Intracranial monitoring
Every patient had a microdialysis catheter (Gold tipped CMA 70 10-mm membrane, CMA, Stockholm, Sweden) and NeurotrendÔ catheter (Codman, Raynham, MA, USA) inserted into the frontal cerebral parenchyma, in conjunction with an intracranial pressure sensor (Codman, Raynham, MA, USA) using a triple-lumen cranial access device (TechniCam, UK). 16 The microdialysis catheter was inserted to a depth of 30 mm and the NeurotrendÔ sensor was inserted to a depth of 45 mm; these depths were calculated so that predominantly white matter was being monitored, and that the oxygen sensor on the NeurotrendÔ catheter was monitoring at approximately the same region as the microdialysis catheter. The catheters were inserted at least 4 h before the intervention studies took place and the positions of the probes were de®ned by obtaining a computed tomography (CT) scan of the head.
Microdialysis
The using the CMA106 pump (CMA, Stockholm, Sweden). Vials were changed at approximately 30-min intervals and were placed onto dry ice and stored at ±70°C for later analysis. The delay from the microdialysis membrane to the collecting vial (dead space) is 17 min, and this was accounted for in the study design. Microdialysis samples were analysed for glucose, lactate, pyruvate, and glycerol using a CMA600 bedside microdialysis analyser (CMA, Stockholm, Sweden).
Cortical function monitoring
EEG burst-suppression, de®ned as bursts of high amplitude theta/delta activity with intervening periods of electrical quiescence, was measured using continuous cortical function monitoring (band-pass 0.1±70 Hz). During each target propofol concentration, the duration (milliseconds) of electrical quiescence vs high amplitude theta/delta activity was measured in order to calculate the burst-suppression ratio. Where a characteristic EEG burst-suppression pattern was absent a burst suppression ratio of 0% was scored.
Propofol intervention
All patients received propofol (Diprivan 2%, AstraZeneca UK Ltd, UK) using a target controlled infusion pump (Master TCI UK, Fresenius Vial S.A., France), incorporating`Diprifusor' software for at least 4 h before the study. All target concentrations during this time were stable and in the range of 2 mg ml ±1 , corresponding to infusion rates of approximately 3±4 mg kg ±1 h ±1 . For each patient, the dose targeted was that which resulted in an infusion rate of propofol similar to the infusion rate being used before the target infusion was commenced. This dose range is within the range speci®ed in the treatment algorithm of our unit. This target concentration was then used as the baseline concentration for the ®rst part of the study. For the second half of the protocol a propofol plasma target concentration 2 mg ml ±1 above the baseline target concentration was used, corresponding to infusion rates of approximately 6±8 mg kg ±1 h ±1 . Any reductions in arterial pressure that occurred when the propofol dose was increased were treated primarily with i.v. colloid infusion but norepinephrine was used if this was not suf®cient. At least 20 min were allowed for the propofol concentration to reach the new target concentration before measurements for the second part of the protocol were begun. Using the`Diprifusor' software this time span is suf®cient to ensure that not only the blood but also the brain concentration has equilibrated with the new dose. 17 Each target plasma propofol concentration was maintained for at least 47 min, during which time microdialysis dialysate was collected, the ®rst 17 min of dialysate having been discarded. During the last 12 min of the period Pb O 2 data were collected and averaged, and paired arterial and jugular venous bloods were taken for calculation of the arterial-venous oxygen gradient (AVDO 2 ).
Apart from minor adjustments to the norepinephrine infusion rate, which were made in order to keep the CPP stable, and minor adjustments to ventilation, which were made in order to keep end-tidal carbon dioxide stable, no other interventions were made during either the baseline period or the CPP augmentation period. 
Oxygen reactivity test

Data analysis
Brain tissue oxygen data were downloaded onto a personal computer using customized software. 20 Mean Pb O 2 values were recorded over 4-min time periods.
The data were analysed using StatView 4 (SAS, Cary, NC, USA) and presented as median (range). Statistical comparisons were made using the Wilcoxon signed rank test with Bonferroni corrections made for multiple comparisons. Correlations were de®ned using linear regression analysis.
Results
Ten patients were studied (seven men, three women). The median age was 36 yr (range 21±53) and the median admission Glasgow Coma Score was 7 (range 3±9). The propofol target concentration at baseline was 2.2 (1.8±2.9) mg ml ±1 and at the higher level 4.2 (3.8±4.9) mg ml
±1
. The Pa CO 2 was comparable at both concentrations of propofol The pattern of injury was classi®ed as evacuated mass lesion in eight patients and as diffuse injury II in two patients. Five patients had large bilateral lesions on CT scan. In eight of the patients, a craniectomy had been performed for evacuation of a subdural haematoma (n=6) or large haemorrhagic contusion (n=2). In the ®ve patients who had predominantly unilateral pathology, intracranial pressure, NeurotrendÔ and microdialysis monitors were sited in the injured hemisphere in two patients. Studies were performed 3 (2±5) days after injury. In one patient the microdialysis and NeurotrendÔ probes were sited in tissue that appeared oedematous on CT scans; however, we were unable to site a jugular bulb catheter in this patient and microdialysis data were unavailable because of failure of the catheter. In one patient there was insuf®cient dialysate to analyse glycerol levels. Subsequent data analysis is therefore based on Pb O 2 data from 10 patients, AVDO 2 data from nine patients, and microdialysis data from nine patients (glycerol, eight patients).
Baseline and interventional physiological data are shown in Tables 1 and 2 .
Increases in target propofol concentrations resulted in varying degrees of burst suppression in all but one of the Flow-metabolism coupling after head injury patients studied; however, despite this evidence of signi®-cant increase in metabolic suppression there were no signi®cant changes in regional or global physiology. Basal regional and global physiology did not predict changes in physiology during the propofol intervention. In one patient, in whom baseline Pb O 2 was in the ischaemic range at baseline (1.2 kPa), there was no clinically signi®cant improvement in Pb O 2 despite a large increase in the burst suppression ratio (from 0 to 51%). Three patients had baseline lactate/pyruvate ratios above normal limits (>27); 21 however, the ratio did not improve signi®-cantly despite a signi®cant increase in burst suppression ratio.
Discussion
We have used target controlled infusions of propofol with a step increase in the target concentration to investigate whether¯ow-metabolism coupling remains intact after traumatic brain injury, and whether metabolic suppression, over and above the normal level of sedation, leads to a reduction in ischaemic burden. The results of this study show that there are no signi®cant changes in cerebral physiology with increased metabolic suppression and indicate that¯ow-metabolism coupling is intact.
An understanding of the signi®cance of our data requires an assessment of the context for these results along with a consideration of the methodological issues involved. We addressed these issues using AVDO 2 and Pb O 2 monitoring, which provide a measure of the relationship between oxygen supply and demand, on a global and regional basis, respectively. We did not show a signi®cant change in either variable, despite a signi®cant suppression of metabolism, suggesting that¯ow-metabolism coupling is intact in our patients and that propofol does not adversely affect this coupling after traumatic brain injury. This result is in line with a study examining the response of middle cerebral artery¯ow velocity and jugular venous saturation to EEG suppression in patients undergoing acoustic neuroma resection. 5 In that study jugular bulb saturations did not change, despite reduced cerebral blood¯ow velocities and increased EEG burst suppression, indicating that¯ow-metabolism coupling remained intact.
However, the literature provides a basis for suspecting that¯ow-metabolism coupling might be deranged in our patient population. Closed head injury is known to disrupt this relationship, at least in a proportion of patients. 9 10 Obrist and colleagues 9 concluded that 45% of head-injured patients exhibit hyperaemia (`luxury perfusion') based on measurements of AVDO 2 and global cerebral blood¯ow, whilst Lee and colleagues 10 concluded that up to 97% of head injured patients have evidence of deranged¯ow metabolism-coupling compared with healthy controls.
Further, several studies suggest that the pharmacological intervention that we used (high dose propofol) may itself have intrinsic vasoactive properties that disrupt¯ow-metabolism coupling. At least four human studies have concluded that propofol does disrupt¯ow-metabolism coupling, with both intrinsic cerebral vasoconstricting and vasodilating properties having been suggested. Two studies have concluded that propofol may reduce cerebral blood ow to a greater extent than it reduces CMRO 2 , that is that propofol has direct vasoconstricting properties and may actually cause cerebral ischaemia. Jansen and colleagues found that in patients undergoing brain tumour surgery there was a signi®cantly lower jugular saturation in patients anaesthetized with propofol than in a matched group anaesthetized with nitrous oxide and iso¯urane; 8 however, they did not ®nd a signi®cant difference in AVDO 2 . Nandate and colleagues compared jugular saturations in three groups of patients undergoing coronary artery bypass grafting and found a signi®cant decrease in jugular bulb saturation 1 h after normothermic cardio-pulmonary bypass with propofol anaesthesia but not with iso¯urane or sevo¯urane anaesthesia. 6 In contrast, two other studies have come to the opposite conclusion, and shown a reduction in oxygen extraction during propofol anaesthesia, indicating that propofol suppresses metabolism to a greater extent than it suppresses blood¯ow during cardio-pulmonary bypass 3 and during induction of anaesthesia in healthy patients. 7 As far as we are aware there is only one other human study examining the effects of propofol-induced EEG burst suppression in head-injured patients. 10 In this study an infusion of propofol, titrated to achieve a degree of EEG burst suppression, led to a signi®cant reduction in intracranial pressure and a signi®cant increase in jugular bulb saturation. Together with evidence that cerebral blood ow did not decline as much as expected during metabolic suppression, the authors concluded that¯ow-metabolism coupling was disordered. In the light of these con¯icting ®ndings, it is important that we consider other possible interpretations of our data. Theoretically our results could be interpreted as resulting from a combination of hyperaemia as a result of disordered ow-metabolism coupling and direct vasoconstriction by propofol. These two processes, when combined, could counteract each other, and result, on average, in no overall change in regional and global oxygen supply±demand relationships. However, such an explanation would demand perfect matching of the two opposing effects across the patients that we studied. This seems unlikely.
It is also important to consider whether our data have an impact on therapies that we use in the context of closed head injury. High dose barbiturates are believed to be useful in the management of refractory intracranial hypertension after traumatic brain injury; 22 however, their use is not recommended for prophylaxis.
11 None of our patients had an intracranial pressure greater than 20 mm Hg and so we are unable to comment on the use of high dose propofol for refractory intracranial hypertension. However, our data certainly suggest that, in the absence of refractory intracranial hypertension, EEG burst suppression using propofol is not a useful therapeutic tool even in areas of the brain that appear to be ischaemic within the time frame of our studies. It is possible that metabolic suppression could result in amelioration of the ischaemic burden in injured tissue over a longer time frame, but our data do not address this possibility. Furthermore, we were unable to determine whether burst-suppression with propofol offers protection for tissue that is not yet ischaemic but, which is at risk of secondary insults. Failure of propofol to reduce ischaemic burden is in line with other data suggesting that EEG burst suppression achieved with propofol does not reduce the incidence of jugular bulb desaturations during cardiopulmonary bypass; 23 however, we were able only to study a small number of patients and we are aware of the possibilities of a type II statistical error in our negative ®ndings.
In conclusion, our data suggest that after traumatic brain injury¯ow-metabolism coupling remains intact during a step increase in propofol infusion rates. Using propofol to achieve EEG burst-suppression does not appear to be a useful therapeutic tool in reducing the level of ischaemic burden in the short-term.
